Importer of Controlled Substances; Notice of Application, 43210-43211 [E6-12171]
Download as PDF
<![CDATA[
43210
Federal Register / Vol. 71, No. 146 / Monday, July 31, 2006 / Notices
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on 202–
205–1810.
INTERNATIONAL TRADE
COMMISSION
DEPARTMENT OF JUSTICE
[Inv. No. 337–TA–560]
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Project Management
Institute
On May
31, 2006, the Commission instituted an
investigation based on a complaint filed
by Ajinomoto Heartland LLC
(‘‘Heartland’’) of Chicago, Illinois under
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337 (71 FR 30958,
May 31, 2006). The complaint, as
amended and supplemented, alleges
violations of section 337 in the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain L-lysine feed products and
genetic constructs for production
thereof by reason of infringement of
claims 13, 15–19, and 21–22 of U.S.
Patent No. 5,827,698 and claims 1, 2, 15,
and 22 of U.S. Patent No. 6,040,160. The
complaint further alleges that an
industry in the United States exists as
required by subsection (a)(2) of section
337. Global Bio-Chem Technology
Group Company Ltd.; Changchun
Dacheng Bio-Chem Engineering
Development Co., Limited; Changchun
Baochen Bio-Chem Development Co.,
Ltd; Changchun Dahe Bio Technology
Development Co. Ltd., all of China, and
Bio-Chem Technology (HK) Limited of
Hong Kong (collectively ‘‘Bio-Chem’’)
were named respondents in the
investigation. Id.
On June 29, 2006, complainant
Heartland filed a motion to amend the
complaint to add its parent company,
Ajinomoto, Inc. (‘‘Ajinomoto’’) as a
complainant. The motion was supported
by the Commission investigative
attorney and Bio-chem. On July 11,
2006, the ALJ granted complainant’s
motion, finding that complainant had
demonstrated good cause for adding
Ajinomoto as a complainant at this time.
No petitions for review of the ID were
filed.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930 (19 U.S.C. 1337) and section
210.42(h) of the Commission’s Rules of
Practice and Procedure (19 CFR
210.42(h)).
AGENCY:
Clint Gerdine, Esq., telephone 202–708–
2310, Office of the General Counsel,
U.S. International Trade Commission,
500 E Street, SW., Washington, DC
20436. Copies of all nonconfidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS–ON–LINE) at
https://edis.usitc.gov. Hearing-impaired
persons are advised that information on
the matter can be obtained by contacting
the Commission’s TDD terminal on 202–
205–1810.
Issued: July 25, 2006.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–12144 Filed 7–28–06; 8:45 am]
Issued: July 24, 2006.
By order of the Commission.
Marilyn R. Abbott.
Secretary to the Commission.
[FR Doc. E6–12143 Filed 7–28–06; 8:45 am]
BILLING CODE 7020–02–P
BILLING CODE 7020–02–P
sroberts on PROD1PC70 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
17:34 Jul 28, 2006
Jkt 208001
Antitrust Division
In the Matter of Certain Nor and Nand
Flash Memory Devices and Products
Containing Same; Notice of Correction
U.S. International Trade
Commission.
ACTION: Correction of the notice of
investigation for the above-captioned
investigation.
SUMMARY: On February 13, 2006, the
Commission published the notice of
investigation for the above-captioned
investigation under Section 337 of the
Tariff Act of 1930, as amended (19
U.S.C. 1337). 71 FR 77576. The
Commission hereby gives notice of the
following corrections to that notice: (1)
In the section labeled SUMMARY, ‘‘flash
memory devices’’ should read ‘‘flash
memory devices and products
containing same,’’ and (2) in the section
labeled Scope of Investigation, ‘‘flash
memory devices’’ should read ‘‘flash
memory devices or products containing
same.’’ The Commission expects that
the administrative law judge will extend
the target date for completion of the
investigation to the extent necessary to
avoid any prejudice to any of the
parties.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
Notice is hereby given that, on June
14, 2006, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Project Management
Institute (‘‘PMI’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing (1) the name and
principal place of business of the
standards development organization,
and (2) the nature and scope of its
standards development activities. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the name and principal place of
business of the standards development
organization is: Project Management
Institute, Newtown Square, PA. The
nature and scope of PMI’s standards
development activities are to develop
standards for the project management
profession that are valued by PMI
members, the marketplace and other
stakeholders. More details regarding
PMI’s standards development activities
can be found at https://www.pmi.org.
Dorothy B. Fountain,
Deputy Director of Operations Antitrust
Division.
[FR Doc. 06–6569 Filed 7–28–06; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 25,
2006, Aptuit, 10245 Hickman Mills
Drive, Kansas City, Missouri 64137,
made application by letter to the Drug
E:\FR\FM\31JYN1.SGM
31JYN1
43211
Federal Register / Vol. 71, No. 146 / Monday, July 31, 2006 / Notices
Enforcement Administration (DEA) for
registration as an importer of Marihuana
(7360), a basic class of controlled
substance in Schedule I.
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than August 30, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–12171 Filed 7–28–06; 8:45 am]
BILLING CODE 4410–09–P
(CFR), this is notice that on October 28,
2005, MGI Pharma, 6611 Tributary
Street, Baltimore, Maryland 21224,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Cocaine (9041), a basic class of
controlled substance listed in Schedules
II.
The company plans to manufacture a
cocaine derivative to be used in
domestic and foreign clinical research
studies.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 29, 2006.
Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–12172 Filed 7–28–06; 8:45 am]
sroberts on PROD1PC70 with NOTICES
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
VerDate Aug<31>2005
17:34 Jul 28, 2006
Jkt 208001
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers for further
manufacture or to manufacture
pharmaceutical dosage forms.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 29, 2006.
Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–12173 Filed 7–28–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on March 22,
2006, Penick Corporation, 33 Industrial
Park Road, Pennsville, New Jersey
08070, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
II:
Drug
Manufacturer of Controlled
Substances; Notice of Application
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Schedule
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
Frm 00118
Fmt 4703
Drug
Schedule
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
PO 00000
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on January 26,
2006, Roche Diagnostics Operations
Inc., Attn: Regulatory Compliance, 9115
Hague Road, Indianapolis, Indiana
46250, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II:
Sfmt 4703
II
II
II
II
II
II
II
Lysergic Acid Diethylamide (7315)
Tetrahydrocannabinol (7370) .......
Alphamethadol (9605) ..................
Phencyclidine (7471) ....................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
E:\FR\FM\31JYN1.SGM
31JYN1
Schedule
I
I
I
II
II
II
II
]]>Agencies
[Federal Register Volume 71, Number 146 (Monday, July 31, 2006)]
[Notices]
[Pages 43210-43211]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12171]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a) authorizing the importation of such a
substance, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on May 25, 2006, Aptuit, 10245 Hickman Mills Drive, Kansas City,
Missouri 64137, made application by letter to the Drug
[[Page 43211]]
Enforcement Administration (DEA) for registration as an importer of
Marihuana (7360), a basic class of controlled substance in Schedule I.
The company plans to import a finished pharmaceutical product
containing cannabis extracts in dosage form for packaging for a
clinical trial study.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than August 30, 2006.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substance listed
in Schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-12171 Filed 7-28-06; 8:45 am]
BILLING CODE 4410-09-P
